Cargando…

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety

Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuhara, Tatsuro, Imai, Kazuhiro, Nakagawa, Taku, Igusa, Ryotaro, Yokota, Hayato, Watanabe, Kana, Suzuki, Aya, Morita, Mami, Onodera, Ren, Inoue, Akira, Miura, Masatomo, Minamiya, Yoshihiro, Maemondo, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526408/ https://www.ncbi.nlm.nih.gov/pubmed/37760942 http://dx.doi.org/10.3390/biomedicines11092501

Ejemplares similares

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method
por: Watanabe, Kana, et al.
Publicado: (2016)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001
por: Watanabe, Kana, et al.
Publicado: (2021)

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
por: Tsubata, Yukari, et al.
Publicado: (2021)

Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing
por: Saito, Yoshitaro, et al.
Publicado: (2016)

Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
por: Miyauchi, Eisaku, et al.
Publicado: (2017)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
por: Yokota, Hayato, et al.
Publicado: (2021)

Surgical therapy for breast cancer liver metastases
por: Terata, Kaori, et al.
Publicado: (2020)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases
por: Goto, Akiteru, et al.
Publicado: (2017)

SUV(max) reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
por: Nagaki, Yushi, et al.
Publicado: (2021)

Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy
por: Nagaki, Yushi, et al.
Publicado: (2021)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Salvage Robotic-Assisted Thoracoscopic Esophagectomy after Definitive Chemoradiotherapy for Clinical T4b Esophageal Cancer: A Case Report
por: Sasamori, Ryohei, et al.
Publicado: (2021)

The complete mitochondrial genome sequences of Japanese earthworms Metaphire hilgendorfi and Amynthas yunoshimensis (Clitellata: Megascolecidae)
por: Seto, Akira, et al.
Publicado: (2021)

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Comparison of the incidences of anastomotic leakage when PDSII or LACLON are used in esophago-gastric conduit handsewn anastomosis after esophagectomy
por: Sato, Yusuke, et al.
Publicado: (2020)

Evaluation of metastatic lymph nodes in cN0 thoracic esophageal cancer patients with inconsistent pathological lymph node diagnosis
por: Wakita, Akiyuki, et al.
Publicado: (2020)

Loco-regional therapy for isolated locoregional lymph node recurrence of breast cancer: focusing on surgical treatment with combined therapy
por: Terata, Kaori, et al.
Publicado: (2020)

Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis
por: Sato, Yusuke, et al.
Publicado: (2021)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Relapsed Myasthenia Gravis after Nivolumab Treatment
por: Mitsune, Ayumi, et al.
Publicado: (2018)

Phase I/II study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer: NJLCG1402
por: Miyauchi, Eisaku, et al.
Publicado: (2021)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Impact of pulmonary rehabilitation on postoperative complications in patients with lung cancer and chronic obstructive pulmonary disease
por: Saito, Hajime, et al.
Publicado: (2017)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Salvage esophagectomy under bilateral thoracotomy after definitive chemoradiotherapy for aorta T4 thoracic esophageal squamous cell carcinoma: Report of a case
por: Nagaki, Yushi, et al.
Publicado: (2015)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
por: Osoegawa, Atsushi, et al.
Publicado: (2021)

Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis
por: Imai, Kazuhiro, et al.
Publicado: (2012)

Potential of combination therapy in EGFR mutated lung cancer
por: Maemondo, Makoto
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_brnncg09o9svik6hkmijodpkbl